Literature DB >> 25964683

Stability of Ertapenem 100 mg/mL in Manufacturer's Glass Vials or Syringes at 4°C and 23°C.

Scott E Walker1, Shirley Law2, William Perks3, John Iazzetta4.   

Abstract

BACKGROUND: Prophylactic administration of ertapenem as a single 1-g IV dose has been shown to reduce sepsis after prostate biopsy.
OBJECTIVE: To evaluate the stability of ertapenem after reconstitution with 0.9% sodium chloride to a final concentration of 100 mg/mL and storage in the manufacturer's original glass vials or polypropylene syringes.
METHODS: On study day 0, 100 mg/mL solutions of ertapenem were retained in the manufacturer's glass vials or packaged in polypropylene syringes and stored at 4°C or 23°C without protection from fluorescent room light. Samples were assayed periodically over 18 days using a validated, stability-indicating liquid chromatographic method with ultra-violet detection. A beyond-use date was determined as the time for the concentration to decline to 90% of the initial (day 0) concentration, based on the fastest degradation rate, with 95% confidence.
RESULTS: Reconstituted solutions stored in the manufacturer's glass vials or polypropylene syringes exhibited a first-order degradation rate, such that 10% of the initial concentration was lost in the first 2.5 days when stored at 4°C or within the first 6.75 h when stored at room temperature (23°C). Analysis of variance showed differences in the percentage remaining due to temperature (p < 0.001) and study day (p < 0.001) but not type of container (p = 0.98). When a 95% CI for the degradation rate was calculated and used to determine a beyond-use date, it was established that more than 90% of the initial concentration would remain for 2.35 days at 4°C and for 0.23 day (about 5 h, 30 min) at room temperature.
CONCLUSIONS: A 100 mg/mL ertapenem solution stored in the manufacturer's glass vial or a polypropylene syringe will retain more than 90.5% of the initial concentration when stored for 48 h at 4°C and for an additional 1 h at 23°C.

Entities:  

Keywords:  ertapenem; high-performance liquid chromatography; polypropylene syringes; stability

Year:  2015        PMID: 25964683      PMCID: PMC4414073          DOI: 10.4212/cjhp.v68i2.1437

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  12 in total

Review 1.  Chemotherapy waste reduction through shelf-life extension.

Authors:  S E Walker; J Iazzetta; C De Angelis; A Gafni
Journal:  Can J Hosp Pharm       Date:  1994-02

2.  Cost effective evaluation of a stability study.

Authors:  S E Walker; Y Hanabusa; G Dranitsaris; W R Bartle; J Iazzetta
Journal:  Can J Hosp Pharm       Date:  1987-08

3.  USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy.

Authors:  Eric S Kastango; Brian D Bradshaw
Journal:  Am J Health Syst Pharm       Date:  2004-09-15       Impact factor: 2.637

4.  Stability studies: five years later.

Authors:  L A Trissel; K P Flora
Journal:  Am J Hosp Pharm       Date:  1988-07

5.  Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C.

Authors:  Jami G Jain; Christina Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Am J Health Syst Pharm       Date:  2014-09-01       Impact factor: 2.637

6.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

7.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

8.  Avoiding common flaws in stability and compatibility studies of injectable drugs.

Authors:  L A Trissel
Journal:  Am J Hosp Pharm       Date:  1983-07

9.  Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions.

Authors:  Michael S McQuade; Vincent Van Nostrand; Joseph Schariter; Jennifer Domsicz Kanike; Richard J Forsyth
Journal:  Am J Health Syst Pharm       Date:  2004-01-01       Impact factor: 2.637

10.  Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate.

Authors:  Giovanni Losco; Rod Studd; Timothy Blackmore
Journal:  BJU Int       Date:  2014-03       Impact factor: 5.588

View more
  1 in total

1.  Stability of Ertapenem 100 mg/mL at Room Temperature.

Authors:  Joseph L Kuti; David P Nicolau
Journal:  Can J Hosp Pharm       Date:  2016-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.